WeVote
Log In

Bill

Bill

HB 1335

requiring health care providers to disclose to patients indirect financial incentives received by the provider.

2026 Regular Session Introduced by Melissa Litchfield and 2 co-sponsors

New Hampshire bill mandates health care providers disclose indirect financial incentives to patients to increase transparency around potential conflicts of interest in clinical decisions.

Inexpedient to Legislate, MA, VV === BILL KILLED ===; 05/14/2026; SJ 12
0
WeVote Research Nonpartisan
Bill Summary · HB 1335

Legislative bill overview

HB 1335 would require health care providers in New Hampshire to disclose to patients any indirect financial incentives they receive that could influence clinical decisions. These incentives might include payments from pharmaceutical companies, device manufacturers, or insurance arrangements that benefit the provider based on treatment decisions. The bill aims to increase transparency around potential conflicts of interest in medical practice.

Why is this important

Patients often make treatment decisions based on their doctor's recommendations without knowing if financial relationships might bias those recommendations. Research shows that indirect financial incentives can subtly influence clinical decisions, potentially affecting whether patients receive more expensive treatments, medications, or procedures. Disclosure requirements help patients make fully informed decisions and allow them to seek second opinions if they have concerns about potential conflicts of interest.

Potential points of contention

  • Implementation burden: Healthcare providers argue disclosure requirements create administrative costs and paperwork, potentially raising healthcare expenses that get passed to patients
  • Definition clarity: Determining what counts as an "indirect financial incentive" is complex—sponsors and stakeholders may dispute whether certain relationships should be disclosed and how detailed disclosures need to be
  • Patient comprehension: Critics question whether average patients understand complex financial relationships between providers and pharmaceutical/device companies, and whether disclosures actually change behavior or create unnecessary confusion

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.